ARHGAP20,Rho GTP酶激活蛋白20抗体
英文名称： Anti-ARHGAP20 antibody
型号:null    抗体货号： HZ-4271R
价格:请致电：010-57128832,18610462672
品牌: 中国/美国    产品商标: hzbscience

ARHGAP20,Rho GTP酶激活蛋白20抗体

产品编号HZ-4271R
英文名称ARHGAP20
中文名称Rho GTP酶激活蛋白20抗体
别 名Arhgap20; KIAA1391; RARHOGAP; RHG20_HUMAN; Rho GTPase activating protein 20; Rho GTPase-activating protein 20; Rho type GTPase activating protein 20; Rho-type GTPase-activating protein 20.
规格价格0.1ml 0.2ml 
说 明 书0.1ml 0.2ml
研究领域肿瘤 细胞生物 信号转导 细胞周期蛋白 G蛋白偶联受体
抗体来源Rabbit
克隆类型Polyclonal
ARHGAP20,Rho GTP酶激活蛋白20抗体交叉反应Human, Mouse, Rat, Dog, Cow, Horse, Rabbit,
产品应用WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量133kDa
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from human ARHGAP20
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
ARHGAP20,Rho GTP酶激活蛋白20抗体PubMedPubMed
产品介绍background:
GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state.

Tissue Specificity:
Expressed predominantly in the brain. Lower expression is found in lymph nodes.

Similarity:
Contains 1 PH domain.
Contains 1 Ras-associating domain.
Contains 1 Rho-GAP domain.

Important Note:
ARHGAP20,Rho GTP酶激活蛋白20抗体This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
 

heterodimer of PMS1 and MLH1.

Subcellular Location:
Nucleus.

DISEASE:
Defects in PMS1 are the cause of hereditary non-polyposis colorectal cancer type 3 (HNPCC3) [MIM:600258]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

PMS1,肿瘤错配修复基因PMS1抗体Similarity:
Belongs to the DNA mismatch repair MutL/HexB family.
Contains 1 HMG box DNA-binding domain.

Database links:
UniProtKB/Swiss-Prot: P54277.1

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.